ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "population studies"

  • Abstract Number: 1299 • ACR Convergence 2024

    Board-Style Rheumatology Teaching for Medicine Residents: Novel Approach to Curriculum Development

    Merve Aksoy*, Shadi Jafari-Esfahani*, Yasaman Ahmadzadeh and Katarzyna Gilek-Seibert, Roger Williams Medical Center, Providence, RI

    Background/Purpose: During their training, internal medicine (IM) residents often have limited exposure to rheumatology, resulting in decreased confidence levels and inadequate scores on the In-training…
  • Abstract Number: 1485 • ACR Convergence 2024

    Genetic Contributions to Systemic Lupus Erythematosus: Concordance Rates in California Twins

    Rashmi Dhital1, Jia Yin Wan2, Kenneth Kalunian3 and Wendy Cozen4, 1UC San Diego, Brentwood, TN, 2Samueli School of Public Health, University of California Irvine, Irvine, CA, 3University of California San Diego, La Jolla, CA, 4University of California Irvine, Irvine

    Background/Purpose: Systemic lupus erythematosus (SLE) is influenced by both genetic and environmental factors. Twin studies in SLE have shown varying levels of concordance. This study…
  • Abstract Number: 1716 • ACR Convergence 2024

    Comparing the Risk of Severe Infections Associated with Different Classes of Biologic or Targeted Synthetic Agents for Inflammatory Arthritis: A Population-based Study

    Kasra Moolooghy1, Hui Xie2, Yufei Zheng3, J. Antonio Avina-Zubieta1 and Diane Lacaille1, 1Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 2Arthritis Research Canada, Simon Fraser University, Vancouver, BC, Canada, 3Arthritis Research Canada, Vancouver, BC, Canada

    Background/Purpose: Various classes of biologic and targeted synthetic DMARDs (b/tsDMARDs) are now available for treatment of inflammatory arthritis (IA), but little information on their relative…
  • Abstract Number: 1873 • ACR Convergence 2024

    Race/Ethnicity and Household Income at the County Level Interacts with the Association of Urbanicity and Lupus Nephritis Mortality

    Snehin Rajkumar1, Eric Yen2 and Ram Singh3, 1UCLA David Geffen School of Medicine, Irvine, CA, 2UCLA, Los Angeles, CA, 3UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: The reasons underlying substantial variation in lupus nephritis (LN) deaths by race/ethnicity remain largely unknown. There are no large population-based studies focused on the…
  • Abstract Number: 1879 • ACR Convergence 2024

    Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023

    Mario Bautista-Vargas1, Adrian Romero-Ocampo2, Juan José Pino Vélez3, juliana Muñoz-Bedoya4 and Diego Rosselli5, 1Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, 2Universidad de Antioquia, Medellín – Colombia, Medellin, Antioquia, Colombia, 3Universidad de Antioquia, Envigado, Antioquia, Colombia, 4Universidad Corpas, Bogotá, Colombia, 5Pontificia Universidad Javeriana, Bogotá, Colombia

    Background/Purpose: The implementation of the SISPRO system enables it to function as a tool capable of collecting pertinent health system data. This information is publicly…
  • Abstract Number: 1882 • ACR Convergence 2024

    30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database

    Shobhit Piplani1, Priyanshu Jain2, Vladimir Jelic3, Clement Tagoe4 and Beverly Johnson5, 1Jacobi Medical Center/North Central Bronx Albert Einstein College of Medicine NYC Health and Hospitals, Bronx, NY, 2Jawaharlal Nehru Medical College, Belgaum, Karnataka, India, Bronx, NY, 3Jacobi Medical Center/North Central Bronx, Bronx, NY, 4Albert Einstein College of Medicine, FRESH MEADOWS, NY, 5Albert Einstein College of Medicine, New York, NY

    Background/Purpose: Rheumatoid Arthirits (RA) is associated with heightened morbidity, diminished quality of life, and increased healthcare expenses. This research aims to bridge this gap by…
  • Abstract Number: 1896 • ACR Convergence 2024

    The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics

    Priyanka Chandratre1, Joht Chandan2, Ben Hammond3, Rasiah Thayakaran3, Samuel Cusworth3, Nicola Adderley3 and Deva Situnayake4, 1The Ottawa Hospital and Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada, 2Institute of Applied Health Research, Birmingham, United Kingdom, 3Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, 4Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom

    Background/Purpose: The prevalence and incidence of Behcet’s syndrome (BS) in the UK is unknown at an unselected population level. BS may be associated with phenotypically…
  • Abstract Number: 0124 • ACR Convergence 2023

    Utility of the 2019 EULAR/ACR SLE Classification Criteria Score as Predictor for Mortality and Hospitalizations in a Population-Based Cohort: The Lupus Midwest Network

    Gabriel Figueroa-Parra1, Andrew Hanson2, Alain Sanchez-Rodriguez3, Jose Meade-Aguilar1, Cynthia Crowson3 and Ali Duarte-Garcia3, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, MN

    Background/Purpose: Patients with SLE experience increased all-cause mortality and have a higher risk of hospitalization than the general population. Recently the classification criteria for SLE…
  • Abstract Number: 0140 • ACR Convergence 2023

    Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database

    Jessica Ellis1, Anita McGrogan2, Neil McHugh2, Ben Mulhearn3, Eleanor Korendowych4, John Pauling5, Ian Bruce6, Jenny Humphreys7 and Sarah Skeoch1, 1University of Bath; Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2University of Bath, Bath, United Kingdom, 3Royal United Hospital Bath | University of Bath, Bath, United Kingdom, 4Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 5North Bristol NHS Trust, Bristol, United Kingdom, 6University of Manchester, Manchester, United Kingdom, 7University of Manchester, Stockport, United Kingdom

    Background/Purpose: The 2019 EULAR/ACR Classification Criteria allow classification of patients with systemic lupus erythematosus (SLE) for research. They reflect updates in current understanding of SLE…
  • Abstract Number: 0239 • ACR Convergence 2023

    Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database

    Michael Garshick1, Haridarshan Patel2, ada Kumar2, Brian LaMoreaux2, Lissa Padnick-Silver2, Louis Dron3, Vinusha Kalatharan3, Vivek Verma3 and Michael Pillinger4, 1NYU School of Medicine/NYU Langone Medical Center, New York, NY, 2Horizon Therapeutics, Deerfield, IL, 3Cytel Canada Inc., Vancouver, BC, Canada, 4New York University Grossman School of Medicine, New York, NY

    Background/Purpose: Gout is a common inflammatory arthropathy characterized by pain, joint swelling, and monosodium urate crystal deposits in joints, organs, and soft tissues.1 While gout…
  • Abstract Number: 0251 • ACR Convergence 2023

    Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study

    Jie Wei1, Hyon K. Choi2, Nicola Dalbeth3, Xiaoxiao Li4, Changjun Li5, Chao Zeng6, Guanghua Lei6 and Yuqing Zhang7, 1Health Management Center, Xiangya Hospital Central South University, Changsha, China, 2Massachusetts General Hospital and Harvard Medical School, Lexington, MA, 3University of Auckland, Auckland, New Zealand, 4Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, 5National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China, 6Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, 7Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA

    Background/Purpose: Recurrent flares are the hallmark of clinical manifestation of gout. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) were associated with a lower risk of incident gout; however,…
  • Abstract Number: 0475 • ACR Convergence 2023

    Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States

    Sabahat Usmani1, Catherine Lavallee2, Maria Antonelli3 and Cuoghi Edens4, 1Weiss Memorial Hospital, Chicago, IL, 2Virginia Tech Carilion School of Medicine, Roanoke, VA, 3MetroHealth System, Cleveland, OH, 4University of Chicago, Chicago, IL

    Background/Purpose: Endometriosis (ENDO) and Polycystic Ovarian Syndrome (PCOS) are underdiagnosed, often debilitating conditions with unknown etiologies that, like rheumatic diseases, affect reproductive-aged women. Recent studies…
  • Abstract Number: 0543 • ACR Convergence 2023

    Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015

    Hilde Haukeland1, Sigrid Reppe Moe1, Cathrine Brunborg2, Antonela Botea3, Nenad Damjanic4, Gro Wivestad5, Heidi Øvreås6, Thea Bøe7, Torhild Garen1, Anniken Orre8, Helga Sanner9, Øyvind Molberg10 and Karoline Lerang9, 1Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 2Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 3Betanien Hospital, Department of Rheumatology, Skien, Norway, 4Ostfold Hospital Trust, Department of Rheumatology,, Grålum, Norway, 5Hospital of Southern Norway Trust, Division of Rheumatology, Department of Medicine, Kristiansand, Norway, 6Lillehammer Hospital for Rheumatic Diseases, Department of Rheumatology, Lillehammer, Norway, 7Vestfold Hospital Trust, Department of Internal Medicine, Tønsberg, Norway, 8Vestre Viken Hospital Trust, Department of Rheumatology, Drammen, Norway, 9Oslo University Hospital, Department of Rheumatology, Nydalen, Norway, 10University of Oslo, Institute of Clinical Medicine, Oslo, Norway

    Background/Purpose: To diagnose Systemic Lupus Erythematosus (SLE), one must understand the phenotype specter and interpret clinical, serological, radiological, and histopathological data, as well as exclude…
  • Abstract Number: 0751 • ACR Convergence 2023

    Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023

    Sharon Abada1, Jing Li1, Gary Tarasovsky2, Cherish Wilson3, Jinoos Yazdany1, Mary Whooley1 and Gabriela Schmajuk3, 1University of California San Francisco, San Francisco, CA, 2San Francisco VA, San Francisco, CA, 3UCSF / SFVA, San Francisco, CA

    Background/Purpose: Patients receiving immunosuppressive therapies are known to have a higher risk of herpes zoster and subsequent complications compared to the general population. The recombinant…
  • Abstract Number: 0977 • ACR Convergence 2023

    Prevalence of Arthritis in the United States: National Estimates from a Population-based Study

    Sumanth Chandrupatla1, Kranti Rumalla2 and Jasvinder Singh1, 1University of Alabama at Birmingham, Birmingham, AL, 2Northwestern School of Medicine, Chicago, IL

    Background/Purpose: Arthritis is the number 1 cause of disability among U.S. adults and reported to cost > $300 billion in direct and indirect costs in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology